ARRY-382 is a small molecule and orally available inhibitor designed to target colony-stimulating factor-1 receptor (CSF1R, also known as cFMS). It functions by binding to and inhibiting cFMS tyrosine kinase activity, thereby disrupting CSF-1-mediated signaling that is implicated in tumor cell proliferation and macrophage regulation.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 1313407-95-2
Afatinib D6
active pharmaceutical ingredient
Gadodiamide
gadolinium-based MRI contrast agent
Arbidol
antiviral active pharmaceutical ingredient
Ethyl 6-bromo-5-hydroxy-1-methyl-2-((phenylthio)methyl)-1H-Indole-3-carboxylate
antiviral active pharmaceutical ingredient
N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]indazol-4-yl]-7-[2-(4-methylpiperazin-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-carboxamide
JUPOTOIJLKDAPF-UHFFFAOYSA-N
CC1=NC(=CC=C1)CN2C3=CC=CC(=C3C(=N2)C4CC4)NC(=O)C5=CN=C6N5C=CC(=C6)OCCN7CCN(CC7)C